Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Roche Holding will acquire AI digital pathology company PathAI in a deal worth up to $1.05 billion, including $750 million upfront and up to $300 million in…
Roche has agreed to shell out up to $1.05 billion to acquire PathAI, the Boston-based artificial intelligence company whose machine learning models analyze…
Roche has signed a definitive merger agreement to acquire PathAI in a transaction valued at up to USD 1.05 billion, comprising USD 750 million in upfront cash…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Roche entered a definitive merger agreement to acquire PathAI for $750M upfront plus up to $300M in milestones (total up to $1.05B). PathAI's AI-powered digital pathology platform will be integrated into Roche's Diagnostics division to scale companion diagnostic algorithms globally, building on the 2021/2024 partnership. Close expected H2 2026.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Roche Holding AG / PathAI, Inc. (this deal) | 2026 | $1.1B | — |
| Roche Holding AG / Chugai Pharmaceutical Co. Ltd. | 2002 | $1.4B | 100 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| Roche Holding AG / Corange Ltd. (Boehringer Mannheim Group) | 1997 | $11.0B | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2007 | $3.4B | 88 |
| Roche Holding AG / Foundation Medicine, Inc. | 2015 | $1.1B | 87 |
| Roche Holding AG / Foundation Medicine, Inc. | 2018 | $5.3B | 85 |
← Browse all deals · How we score deals
More: 2026 deals · Roche Holding AG deals · Oncology deals